CEPHEUS FDA Approval: Daratumumab and Hyaluronidase-fihj Plus VRd for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. Approval was based on the Phase III CEPHEUS trial, which demonstrated significantly higher minimal residual disease (MRD) negativity […]
